checkAd
    Startseite > Aktien > ALX Oncology Holdings > Nachrichten
    ALX Oncology Holdings
    Aktie
    ISIN: US00166B1052 WKN: A2P79Z SYM: ALXO Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    8,3900
     
    USD
    -0,59 %
    -0,0500 USD
    Letzter Kurs 15:41:39 Nasdaq
    Geldkurs
    15:41:41
    8,2700
     
    USD
    100 STK
    Briefkurs
    15:41:41
    8,4500
     
    USD
    200 STK

    ALX Oncology Holdings Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
    02.06.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
    29.05.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
    09.05.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Appoints Allison Dillon as Chief Business Officer
    07.05.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
    30.04.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
    24.04.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
    09.04.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    07.03.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
    05.03.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    03.01.24 · globenewswire · ALX Oncology Holdings
    ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    13.11.23 · globenewswire · ALX Oncology Holdings
    ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    10.10.23 · globenewswire · ALX Oncology Holdings